基蛋生物(603387.SH):擬投資建設智能化生產研發基地
格隆匯7月4日丨基蛋生物(603387.SH)公佈,為滿足公司未來發展規劃對經營場所的需求,優化資源配置,為公司的可持續長遠發展提供有力的硬件保障,公司投資建設智能化生產研發基地。該項目佔地面積約40,010.27平方米,總建築面積約65,538.81平方米,主要建設內容包含四層綜合廠房、高標準倉儲中心及配套研發辦公設施。項目建成後,將主要形成化學發光、生化、血球等產品線儀器及試劑的產能。公司已取得項目所需建設用地以及《投資項目備案證》《施工許可證》,擬進行開工建設,並按計劃持續推進。預計總投資約1.5億元人民幣,包含土地價款、建築主體工程及配套設施工程費用。項目最終投資總額以實際投資金額為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.